FindMyKOL

Ioannis Chatzizisis, MD, PhD

Basic profile

University of Miami

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionCoral Gables, FL · SoutheastSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLFindMyKOL type: RegionalLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH funding2023–2023Why? →

Ioannis Chatzizisis is a Cardiology physician affiliated with University of Miami.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
21companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2023–2023

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Industry payments

21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • CathWorks
    Program year20254 paymentsResearch
    $36,243
  • Medtronic
    Program year20251 paymentResearch
    $16,560
  • HEARTFLOW, INC.
    Program year20257 payments
    $1,784
All 37 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    78.6%
    Statin22%
    Rosuvastatin Calcium65%Atorvastatin Calcium35%
    Part D≥34 patients
    Beta blocker10.7%
    Metoprolol Succinate44%Metoprolol Tartrate38%Carvedilol18%
    Part D<11 patients

    + 11 more classes in this area

  • Blood & clotting

    13.9%
    Factor Xa inhibitor6.9%
    Eliquis100%
    Part D<11 patients
    P2Y12 inhibitor6.9%
    Clopidogrel100%
    Part D≥15 patients
  • Metabolism & gastrointestinal

    7.6%
    SGLT2 inhibitor7.6%
    Farxiga63%Jardiance38%
    Part D<11 patients
Where care is delivered (Part B)92.5% facility · 7.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2023–2023 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”